Hladiny C1q a anti C1q protilátek u nemocných se SLE- spojené nádoby aktivity SLE?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F04%3A00001777" target="_blank" >RIV/61989592:15110/04:00001777 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Levels of C1q and Anti C1q Antibodies in SLE Patients - Communicating Vessels of Disease Activity?

Popis výsledku v původním jazyce

Anti C1q antibody is the most common antibody targeting complement system in SLE. The aim of the study was to evaluate anti C1q and C1q levels in the group of SLE patients with regards to the clinical parameters of the disease and disease activity indices. Methods: C1q levels were measured by immunodiffusion according Mancini, anti C1q antibodies by ELISA method in 55 patients with SLE. The mean serum levels of anti-C1q antibodies were 89+/-103 IU/ml and of C1q 145+/-52mg/l. The significant difference in C1q antibodies levels was found between individuals with and without lupus nephritis (117.5+/-52 IU/ml vs. 28.2+/-12.2 IU/ml, p=0.0001) and between active and non- active SLE (154.6+/-115 IU/ml vs. 50.6+/-73, p=0.001). C1q complement component was statistically lower in patients with lupus nephritis (144+/-30 mg/l vs. 175+/-50 mg/ml, p=0.002) and in active patients (138+/-40 mg/l vs. 202+/-20mg/l, p=0.001). If both parameters are measured together, they seem to have a mirror like patte

Název v anglickém jazyce

Levels of C1q and Anti C1q Antibodies in SLE Patients - Communicating Vessels of Disease Activity?

Popis výsledku anglicky

Anti C1q antibody is the most common antibody targeting complement system in SLE. The aim of the study was to evaluate anti C1q and C1q levels in the group of SLE patients with regards to the clinical parameters of the disease and disease activity indices. Methods: C1q levels were measured by immunodiffusion according Mancini, anti C1q antibodies by ELISA method in 55 patients with SLE. The mean serum levels of anti-C1q antibodies were 89+/-103 IU/ml and of C1q 145+/-52mg/l. The significant difference in C1q antibodies levels was found between individuals with and without lupus nephritis (117.5+/-52 IU/ml vs. 28.2+/-12.2 IU/ml, p=0.0001) and between active and non- active SLE (154.6+/-115 IU/ml vs. 50.6+/-73, p=0.001). C1q complement component was statistically lower in patients with lupus nephritis (144+/-30 mg/l vs. 175+/-50 mg/ml, p=0.002) and in active patients (138+/-40 mg/l vs. 202+/-20mg/l, p=0.001). If both parameters are measured together, they seem to have a mirror like patte

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

<a href="/cs/project/GP310%2F02%2FP070" target="_blank" >GP310/02/P070: Hodnocení ukazatelů apoptózy lymfocytů a neurofilních polymorfonukleárů v průběhu systémového lupus erythematodes</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2004

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of the Rheumatic Diseases

ISSN

0003-4967

e-ISSN

—

Svazek periodika

63

Číslo periodika v rámci svazku

S 1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

1

Strana od-do

214

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—